CRTC2 reportedly promotes hepatocellular carcinoma growth through Wnt/β-catenin pathway activation while downregulating the PD-L1/PD-1 axis, thereby enhancing immunotherapy resistance (16). Here, CD274 is linked to hepatocellular carcinoma.